traditional-medicine-2016_scientifictracks-workshop

5 / 38

Volume 5, Issue 2 (Suppl) J Tradi Med Clin Natur
ISSN: JTMCN, an open access journal
Page 28
Notes:
Traditional Medicine 2016
September 14-16, 2016
conferenceseries.com
September 14-16, 2016 Amsterdam, Netherlands
6th International Conference and Exhibition on
Traditional & Alternative Medicine
American ginseng suppresses colitis and prevents colon cancer in mice: Understanding the mechanisms
and the molecules
Lorne J Hofseth
University of South Carolina, USA
Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the colon associated with an increased colon cancer risk.
Although inflammation plays a key role, both the mechanistic understanding and the safe and effective treatment of ‘colitis’, are
limited. Complementary and alternative medicines (CAMs) can offer a safe and effective option for the treatment of IBD. Over the
past decade, we have shown that American Ginseng (AG) and a fraction of AG generated using Hexane as a solvent suppresses
colitis and prevents colon cancer in mice. Mechanistically, it appears that key known nodes in the inflammation to cancer sequence,
including iNOS, p53, miRNAs (particularly miRNA-29b), and Nrf2, are involved. AG and some of its ingredients also suppress
oxidative stress, and DNA damage associated with free radical production during inflammation. Such findings offer an explanation
to the observation that AG and HAG prevent colon cancer associated with colitis. Recently, we have isolated one particularly active
ingredient from AG, called Panaxynol. Excitingly, Panaxynol targets macrophages for DNA damage and associated cellular apoptosis
in vitro and in vivo. Preliminary findings indicate that Panaxynol suppresses macrophage-driven mouse models of disease, including
colitis. We are currently drilling deeper to understand the mechanisms. Overall, we have shown in many studies that AG suppresses
colitis, and are in a position to begin clinical trials to show efficacy in humans.
Biography
Lorne J Hofseth completed his PhD from Simon Fraser University, Canada in 1996. After completing Post-docs at Michigan State University and the National
Cancer Institute, he joined the faculty in the College of Pharmacy, University of South Carolina. He is a full Professor, and is currently the Director of Graduate
Studies. He has published over 75 articles, and supports his program through several NIH grants.
Lorne J Hofseth, J Tradi Med Clin Natur 2016, 5:2 (Suppl)